Table 1.

Baseline Characteristics

	Measures
NOACs	492*
Dabigatran	181/492 (36.8%)
Reversal with idarucizumab	44/181 (24.2%)
Rivaroxaban	215/492 (43.7%)
Apixaban	40/492 (8.1%)
NOACs not specified	56/492 (11.4%)
Age, y†	Median, 77 (IQR, 68–83)
Women	233/492 (47.4%)
NOAC last intake before stroke, h†	Median, 8 (IQR, 2.5–14.5)
≤12	80/145 (55.2%)
13–24	43/127 (33.9%)
>24	10/130 (7.7%)
Precise time/range not reported	347/492 (70.5%)
Laboratory†
Prolonged PT	7/16 (43.8%)
Prolonged aPTT	34/124 (27.4%)
Prolonged TT in dabigatran	23/27 (85.2%)
TT, dTT, or dabigatran concentration in dabigatran	37/94 (39.4%)
Anti-Xa assay in rivaroxaban or apixaban	43/91 (47.3%)
NIHSS on admission	Median, 10 (IQR, 6–16)†

dTT indicates diluted thrombin time; IQR, interquartile range; NIHSS, National Institutes of Health Stroke Scale; NOAC, non–vitamin K antagonist oral anticoagulants; and TT, thrombin time.

^*Includes 30 patients receiving intra-arterial treatment.

^†Among patients with complete individual-level data.